

**KENNEDY KRIEGER INSTITUTE,
INC. AND AFFILIATES**

**Reports on Federal Awards in Accordance with
Uniform Guidance**

June 30, 2022

Federal Entity Identification Number 52-1524965

Kennedy Krieger Institute, Inc. and Affiliates

Index

June 30, 2022

	Page(s)
Part I - Financial Statements and Schedule of Expenditures of Federal Awards	
Report of Independent Auditors Consolidated Financial Statements	1-3
Consolidated Balance Sheets	4
Consolidated Statements of Operations and Changes in Net Assets	5-6
Consolidated Statements of Cash Flows	7
Notes to Consolidated Financial Statements	8-33
Report of Independent Auditors on Supplemental Consolidating Financial Statements	34
Supplemental Combining Financial Statements	35-40
Notes to Supplemental Consolidating Financial Statements	41
Schedule of Expenditures of Federal Awards	42-56
Notes to Schedule of Expenditures of Federal Awards	57-58
Part II - Reports on Compliance and Internal Control⁶⁵	
Report of Independent Auditors on Internal Control over Financial Reporting and on Compliance and Other Matters Based on an Audit of Financial Statements Performed in Accordance with Government Auditing Standards	59-60
Report of Independent Auditors on Compliance with Requirements That Could Have a Direct and Material Effect on Each Major Program and on Internal Control Over Compliance in Accordance with the OMB Uniform Guidance	61 -63
Part III – Schedule of Findings and Questioned Costs⁷⁰	
Schedule of Findings and Questioned Costs	64-66
Summary Schedule of Prior Audit Findings	67
Management’s Views and Corrective Action Plan	68-69

Part I
Financial Statements and
Schedule of Expenditures of Federal Awards
Year Ended June 30, 2022



Report of Independent Auditors

To the Board of Directors of Kennedy Krieger Institute, Inc. and Affiliates

Opinion

We have audited the accompanying consolidated financial statements of Kennedy Krieger Institute, Inc. and Affiliates (the "Institute"), which comprise the consolidated balance sheets as of June 30, 2022 and 2021, and the related consolidated statements of operations and changes in net assets and of cash flows for the years then ended, including the related notes (collectively referred to as the "consolidated financial statements").

In our opinion, the accompanying consolidated financial statements present fairly, in all material respects, the consolidated financial position of the Institute as of June 30, 2022 and 2021, and the results of their operations, changes in their net assets, and their cash flows for the years then ended in accordance with accounting principles generally accepted in the United States of America.

Basis for Opinion

We conducted our audit in accordance with auditing standards generally accepted in the United States of America (US GAAS) and the standards applicable to financial audits contained in *Government Auditing Standards*, issued by the Comptroller General of the United States. Our responsibilities under those standards are further described in the Auditors' Responsibilities for the Audit of the Consolidated Financial Statements section of our report. We are required to be independent of the Institute and to meet our other ethical *responsibilities*, in accordance with the relevant ethical requirements relating to our audit. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.

Responsibilities of Management for the Consolidated Financial Statements

Management is responsible for the preparation and fair presentation of the consolidated financial statements in accordance with accounting principles generally accepted in the United States of America, and for the design, implementation, and maintenance of internal control relevant to the preparation and fair presentation of consolidated financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, management is required to evaluate whether there are conditions or events, considered in the aggregate, that raise substantial doubt about the Institute's ability to continue as a going concern for one year after the date the financial statements are issued.

Auditors' Responsibilities for the Audit of the Consolidated Financial Statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditors' report that includes our opinion. Reasonable assurance is a high level of assurance but is not absolute assurance



and therefore is not a guarantee that an audit conducted in accordance with US GAAS and *Government Auditing Standards* will always detect a material misstatement when it exists. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control. Misstatements are considered material if there is a substantial likelihood that, individually or in the aggregate, they would influence the judgment made by a reasonable user based on the financial statements.

In performing an audit in accordance with US GAAS and *Government Auditing Standards*, we:

- Exercise professional judgment and maintain professional skepticism throughout the audit.
- Identify and assess the risks of material misstatement of the consolidated financial statements, whether due to fraud or error, and design and perform audit procedures responsive to those risks. Such procedures include examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated financial statements.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Institute's internal control. Accordingly, no such opinion is expressed.
- Evaluate the appropriateness of accounting policies used and the reasonableness of significant accounting estimates made by management, as well as evaluate the overall presentation of the consolidated financial statements.
- Conclude whether, in our judgment, there are conditions or events, considered in the aggregate, that raise substantial doubt about the Institute's ability to continue as a going concern for a reasonable period of time.

We are required to communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit, significant audit findings, and certain internal control-related matters that we identified during the audit.

Supplemental Information

Our audit was conducted for the purpose of forming an opinion on the consolidated financial statements as a whole. The accompanying schedule of expenditures of federal awards for the year ended June 30, 2022 is presented for purposes of additional analysis as required by Title 2 U.S. Code of Federal Regulations Part 200, Uniform Administrative Requirements, Cost Principles, and Audit Requirements for Federal Awards (Uniform Guidance) and is not a required part of the consolidated financial statements. Such information is the responsibility of management and was derived from and relates directly to the underlying accounting and other records used to prepare the consolidated financial statements. The information has been subjected to the auditing procedures applied in the audit of the consolidated financial statements and certain additional procedures, including comparing and reconciling such information directly to the underlying accounting and other records used to prepare the consolidated financial statements or to the consolidated financial statements themselves, and other additional procedures, in accordance with auditing standards generally accepted in the United States of America. In our opinion, the schedule of expenditures of federal awards is fairly stated, in all material respects, in relation to the consolidated financial statements taken as a whole.



Other Reporting Required by Government Auditing Standards

In accordance with Government Auditing Standards, we have also issued our report dated October 14, 2022 on our consideration of the Institute's internal control over financial reporting and on our tests of its compliance with certain provisions of laws, regulations, contracts and grant agreements and other matters for the year ended June 30, 2022. The purpose of that report is solely to describe the scope of our testing of internal control over financial reporting and compliance and the results of that testing and not to provide an opinion on the effectiveness of internal control over financial reporting or on compliance. That report is an integral part of an audit performed in accordance with Government Auditing Standards in considering Institute's internal control over financial reporting and compliance.

PricewaterhouseCoopers LLP

Baltimore, Maryland
October 14, 2022

**Schedule of Expenditures of Federal Awards and
Notes to Schedule of Expenditures of Federal Awards**

Kennedy Krieger Institute, Inc. and Affiliates

Schedule of Expenditures of Federal Awards

Year Ended June 30, 2022

Cluster/Federal Program	Entity	Assistance Listing Number	Pass Through Entity	Grant award number or pass-through entity identification number	Federal Expenditures	
					Total	Passed through to subrecipients
Research and Development Cluster- Direct Awards						
Department of Health and Human Services						
Centers for Disease Control & Prevention						
Maternal Child Health Careers/Research Initiatives-Undergrad	R	93.456		U50 MN000004-04	\$ 173,480	\$ -
Maternal Child Health Careers/Research Initiatives-Undergrad	R	93.456		U50 MN000004-04	105,934	0
Maternal Child Health Careers/Research Initiatives-Undergrad	R	93.456		U50 MN000004-04	25,199	25,199
Maternal Child Health Careers/Research Initiatives-Undergrad	R	93.456		U50 MN000004-04	12,829	12,829
Maternal Child Health Careers/Research Initiatives-Undergrad	R	93.456		U50 MN000004-04	535,068	0
Maternal Child Health Careers/Research Initiatives-Undergrad	R	93.456		U50 MN000004-04	449,387	0
Maternal Child Health Careers/Research Initiatives-Undergrad	R	93.456		U50 MN000004-04	28,353	28,353
Maternal Child Health Careers/Research Initiatives-Undergrad	R	93.456		U50 MN000004-04	24,948	24,948
National Institute of Health						
Clinical and Neuroimaging Phenotypes of Neurological Disorders In Pediatric Sickle Cell Disease	R	93.839		K 23 HI133455-04A	59,273	0
MRI-based Quantitative Brain Oximetry for Sickle Cell Disease	R	93.839		K25 HL145129-02	7,302	7,302
MRI-based Quantitative Brain Oximetry for Sickle Cell Disease	R	93.839		K25 HL145129-03	52,046	10,346
MRI-based Quantitative Brain Oximetry for Sickle Cell Disease	R	93.839		K25 HL145129-04	1,912	0
Neuroimaging, Neurocognitive & Plasma Protein Markers in Sickle Cell	R	93.839		R03 HL158636-01	36,928	0
Non-Contrast-Enhanced Velocity-Selective MR Angiography	R	93.837		R01HL138182-03	19,301	0
Non-Contrast-Enhanced Velocity-Selective MR Angiography	R	93.837		R01HL138182-04	234,159	0
Non-Contrast-Enhanced Velocity-Selective MR Angiography	R	93.837		R01HL138182-05	104,504	0
Velocity-Selective Arterial Spin Labeling based Perfusion Mapping for Cerebrovascular Diseases	R	93.837		R01HL144751-02	242,473	5,300
Velocity-Selective Arterial Spin Labeling based Perfusion Mapping for Cerebrovascular Diseases	R	93.837		R01HL144751-03	84,000	0
MRI Based Phosphocreatine Mapping Method to Assess Patients with Peripheral Arterial Disease	R	93.837		R01HL149742-01A1	215,182	16,273
MRI Based Phosphocreatine Mapping Method to Assess Patients with Peripheral Arterial Disease	R	93.837		R01HL149742-01A1	352,360	0
MRI Bimodal Imaging for Non Invasive Tracking of Extracellular Vesicles	R	93.837		R33 HL161756-01	92,073	0
Resources for Quantitative Functional MRI	R	93.286		P41 RR15241-18 Suppl	901	0
Resources for Quantitative Functional MRI	R	93.286		P41 RR15241-19	878	0
Resources for Quantitative Functional MRI	R	93.286		P41 RR15241-20	549,851	0
Resources for Quantitative Functional MRI	R	93.286		P41 RR15241-20 Miller sub	75,470	75,470
Resources for Quantitative Functional MRI	R	93.286		P41 RR15241-20 Caffo sub	7,069	7,069
Novel Approaches for CEST Labeling, Detection, Quantification and Translation	R	93.286		5 R01 EB015032-07	624	0
Novel Approaches for CEST Labeling, Detection, Quantification and Translation	R	93.286		5 R01 EB015032-08	427,422	0
Development and Translation of D-Glucose as a Diagnostic Agent for MRI	R	93.286		R01EB019934-05	210,147	0
Sensitivity Enhanced MRI Imaging of Receptor Binding in Breast Cancer	R	93.286		R21EB025295-03A	94,889	0
Gastric Electrical Slow Wave Functional MRI of the Human Brain	R	93.286		R21EB030009-01	178,100	14,425

The accompanying notes are an integral part of the schedule of expenditures of federal awards.

Kennedy Krieger Institute, Inc. and Affiliates
Schedule of Expenditures of Federal Awards
Year Ended June 30, 2022

Cluster/Federal Program	Entity	Assistance Listing Number	Pass Through Entity	Grant award number or pass-through entity identification number	Federal Expenditures	
					Total	Passed through to subrecipients
MRI Resource for Physiologic, Metabolic & Anatomic Biomarkers	R	93.286		P41EB031771-01	\$ 400,860	\$ -
MRI Resource for Physiologic, Metabolic & Anatomic Biomarkers	R	93.286		P41EB031771-01	67,291	0
MRI Resource for Physiologic, Metabolic & Anatomic Biomarkers	R	93.286		P41EB031771-01 -SUB	93,857	93,857
MRI Resource for Physiologic, Metabolic & Anatomic Biomarkers	R	93.286		P41EB031771-01	91,830	0
MRI Resource for Physiologic, Metabolic & Anatomic Biomarkers	R	93.286		P41EB031771-01 - SUB	27,763	27,763
MRI Resource for Physiologic, Metabolic & Anatomic Biomarkers	R	93.286		P41EB031771-01	79,909	0
MRI Resource for Physiologic, Metabolic & Anatomic Biomarkers	R	93.286		P41EB031771-01	57,413	0
MRI Resource for Physiologic, Metabolic & Anatomic Biomarkers	R	93.286		P41EB031771-01	57,096	0
MRI Resource for Physiologic, Metabolic & Anatomic Biomarkers	R	93.286		P41EB031771-01	19,968	0
MRI Resource for Physiologic, Metabolic & Anatomic Biomarkers	R	93.286		P41EB031771-01	14,166	0
MRI Resource for Physiologic, Metabolic & Anatomic Biomarkers	R	93.286		P41EB031771-01	17,953	0
MRI Resource for Physiologic, Metabolic & Anatomic Biomarkers	R	93.286		P41EB031771-01	14,853	0
MRI Resource for Physiologic, Metabolic & Anatomic Biomarkers	R	93.286		P41EB031771-01	11,778	0
MRI Resource for Physiologic, Metabolic & Anatomic Biomarkers	R	93.286		P41EB031771-01	10,893	0
Resident Training in Brain Injury Rehab	R	93.865		5T32HD007414-27	111,277	0
Resident Training in Brain Injury Rehab	R	93.865		5T32HD007414-28	84,831	0
Resident Training in Brain Injury Rehab	R	93.865		5T32HD007414-29	23,179	0
Mechanism & Rehabilitation of Cerebella Ataxia	R	93.865		R01 HD40289-16A	12,168	0
Mechanism & Rehabilitation of Cerebella Ataxia	R	93.865		R01 HD40289-17A	48,650	0
Mechanism & Rehabilitation of Cerebella Ataxia	R	93.865		R01 HD40289-17A	4,351	4,351
Mechanism & Rehabilitation of Cerebella Ataxia	R	93.865		R01 HD40289-18A	251,648	0
Mechanism & Rehabilitation of Cerebella Ataxia	R	93.865		R01 HD40289-19A	133,881	0
Human Locomotors Plasticity in Health and Disease	R	93.865		R37 NS090610-14	134,995	0
Human Locomotors Plasticity in Health and Disease	R	93.865		R37 NS090610-15	244,536	0
Human Locomotors Plasticity in Health and Disease	R	93.865		R37 NS090610-15 CELNIK SU	20,801	20,801
Human Locomotors Plasticity in Health and Disease	R	93.865		R37 NS090610-15 ZIPUNN SU	26,741	26,741
Human Locomotors Plasticity in Health and Disease	R	93.865		R37 NS090610-16	(12,435)	0
Delineating Subtypes of Self-Injurious Behavior Maintained by Automatic	R	93.865		R01 HD076653-06	620	620
Delineating Subtypes of Self-Injurious Behavior Maintained by Automatic	R	93.865		R01 HD076653-07	96,517	12,064
Delineating Subtypes of Self-Injurious Behavior Maintained by Automatic	R	93.865		R01 HD076653-08	224,232	0
Delineating Subtypes of Self-Injurious Behavior Maintained by Automatic	R	93.865		R01 HD076653-09	188	0
Intellectual and Developmental Disabilities Research Centers 2013	R	93.865		U54 HD079123-06	(403)	0
Intellectual and Developmental Disabilities Research Centers 2013	R	93.865		U54 HD079123-06	38	0
Intellectual and Developmental Disabilities Research Centers 2013	R	93.865		P50HD103538 CLIN	(2,130)	0
Intellectual and Developmental Disabilities Research Centers 2013	R	93.865		P50HD103538-01 RESEARCH	81	0
Intellectual and Developmental Disabilities Research Centers 2013	R	93.865		P50HD103538 NEURO	3,453	0
Intellectual and Developmental Disabilities Research Centers 2013	R	93.865		P50HD103538 BEH PHENOTY	23	0
Intellectual and Developmental Disabilities Research Centers 2013	R	93.865		IDDRC-JHU SUB VOLK	4,436	4,436
Intellectual and Developmental Disabilities Research Centers 2013	R	93.865		IDDRC-JHU SUB KANNAN	50,164	50,164
Intellectual and Developmental Disabilities Research Centers 2013	R	93.865		IDDRC-JHU SUB VOLK_II	35,488	35,488
Intellectual and Developmental Disabilities Research Centers 2013	R	93.865		IDDRC-JHU SUB MILLER	1,741	1,741
Intellectual and Developmental Disabilities Research Centers 2013	R	93.865		IDDRC-JHU SUB LIN	24,008	24,008
Intellectual and Developmental Disabilities Research Centers 2013	R	93.865		IDDRC-JHU SUB DOHENY	27,793	27,793
Intellectual and Developmental Disabilities Research Centers 2013	R	93.865		P50HD103538-02 ADMIN	165,420	0
Intellectual and Developmental Disabilities Research Centers 2013	R	93.865		P50HD103538 CLIN	269,968	0

The accompanying notes are an integral part of the schedule of expenditures of federal awards.

Kennedy Krieger Institute, Inc. and Affiliates

Schedule of Expenditures of Federal Awards

Year Ended June 30, 2022

Cluster/Federal Program	Entity	Assistance Listing Number	Pass Through Entity	Grant award number or pass-through entity identification number	Federal Expenditures	
					Total	Passed through to subrecipients
Intellectual and Developmental Disabilities Research Centers 2013	R	93.865		P50HD103538-02 RESEARCH	\$ 147,185	\$ -
Intellectual and Developmental Disabilities Research Centers 2013	R	93.865		P50HD103538 NEURO IMAG	24,729	0
Intellectual and Developmental Disabilities Research Centers 2013	R	93.865		P50HD103538 BEH PHENOTY	151,218	0
Intellectual and Developmental Disabilities Research Centers 2013	R	93.865		P50HD103538 DS CONNECT	53,304	0
Intellectual and Developmental Disabilities Research Centers 2013	R	93.865		P50HD103538 SUB VOLK	35,231	35,231
Intellectual and Developmental Disabilities Research Centers 2013	R	93.865		P50HD103538 SUB KANNAN	20,044	20,044
Intellectual and Developmental Disabilities Research Centers 2013	R	93.865		P50HD103538 SUB VOLK_II	63,386	63,386
Intellectual and Developmental Disabilities Research Centers 2013	R	93.865		P50HD103538 SUB MILLER	16,318	16,318
Intellectual and Developmental Disabilities Research Centers 2013	R	93.865		P50HD103538 SUB LIN	33,985	33,985
Intellectual and Developmental Disabilities Research Centers 2013	R	93.865		P50HD103538 SUB DOHENY	76,407	76,407
Intellectual and Developmental Disabilities Research Centers 2013	R	93.865		P50HD103538 ADMIN	13,479	0
Intellectual and Developmental Disabilities Research Centers 2013	R	93.865		P50HD103538 CLIN	16,460	0
Intellectual and Developmental Disabilities Research Centers 2013	R	93.865		P50HD103538 RESEARCH	10,214	0
Intellectual and Developmental Disabilities Research Centers 2013	R	93.865		P50HD103538 NEURO IMAGI	2,580	0
Intellectual and Developmental Disabilities Research Centers 2013	R	93.865		P50HD103538 BEH PHENOTY	14,056	0
Mechanisms Regulating KCC@ Hypofunction	R	93.865		R01 HD090884-02	384	0
Mechanisms Regulating KCC@ Hypofunction	R	93.865		R01 HD090884-03	9,728	0
Mechanisms Regulating KCC@ Hypofunction	R	93.865		R01 HD090884-04	87,469	0
Mechanisms Regulating KCC@ Hypofunction	R	93.865		R01 HD090884-05	122,543	0
Subtle Motor Functioning and Functional Connectivity in Youth After Mild TBI	R	93.865		R01HD090266-02	9,115	0
Subtle Motor Functioning and Functional Connectivity in Youth After Mild TBI	R	93.865		R01HD090266-03	179,881	0
Subtle Motor Functioning and Functional Connectivity in Youth After Mild TBI	R	93.865		R01HD090266-03 CAFFO	2,586	2,586
Subtle Motor Functioning and Functional Connectivity in Youth After Mild TBI	R	93.865		R01HD090266-03 TEKES	-	0
Subtle Motor Functioning and Functional Connectivity in Youth After Mild TBI	R	93.865		R01HD090266-04	342,902	0
Subtle Motor Functioning and Functional Connectivity in Youth After Mild TBI	R	93.865		R01HD090266-CAFFO	19,511	19,511
Subtle Motor Functioning and Functional Connectivity in Youth After Mild TBI	R	93.865		R01HD090266- TEKES	12,766	12,766
Subtle Motor Functioning and Functional Connectivity in Youth After Mild TBI	R	93.865		R01HD090266-05	133,140	0
Subjective Valuation of Ohysical Effort in Health and Disease	R	93.865		R01HD097619-01A1	68,309	0
Subjective Valuation of Ohysical Effort in Health and Disease	R	93.865		R01HD097619-02	212,382	0
Subjective Valuation of Ohysical Effort in Health and Disease	R	93.865		R01HD097619-02 CELNIK	15,120	15,120
Subjective Valuation of Ohysical Effort in Health and Disease	R	93.865		R01HD097619-02	338,319	1,447
Subjective Valuation of Ohysical Effort in Health and Disease	R	93.865		R01HD097619-02 CELNIK	17,581	17,581
Identifying Precursors to Severe Problem Behavior	R	93.865		R03HD096180-02A	13,300	0
Preparing for a Clinical Trial in Kabuki Syndrome	R	93.865		K23HD101646-01	5,743	0
Preparing for a Clinical Trial in Kabuki Syndrome	R	93.865		K23HD101646-02	160,944	0
The Role of Executive Functions in Reading & Reading Remediation	R	93.865		R01HD086011-06	1,492	0
Anomalous Motor System Physiology in ADHD	R	93.242		R01MH078160-11	84,578	0
Anomalous Motor System Physiology in ADHD	R	93.242		R01MH078160-12	314,143	0
Adolescent Changes in Brain and Behavior in Boys and Girls with ADHD	R	93.242		R01MH085328-12A1	2,941	0

The accompanying notes are an integral part of the schedule of expenditures of federal awards.

Kennedy Krieger Institute, Inc. and Affiliates

Schedule of Expenditures of Federal Awards

Year Ended June 30, 2022

Cluster/Federal Program	Entity	Assistance Listing Number	Pass Through Entity	Grant award number or pass-through entity identification number	Federal Expenditures	
					Total	Passed through to subrecipients
Adolescent Changes in Brain and Behavior in Boys and Girls with ADHD	R	93.242		R01MH085328-13A1	\$ (1,726)	\$ -
Adolescent Changes in Brain and Behavior in Boys and Girls with ADHD	R	93.242		R01MH085328-14A1	36,077	0
Virtual Brain Electrode (VIBE) for Imaging Neuronal Activity	R	93.242		R24MH109085-03	(56)	0
Visual-Motor Development in Infants at High Risk for Autism	R	93.242		K01MH109766-02	10,148	0
Visual-Motor Development in Infants at High Risk for Autism	R	93.242		K01MH109766-03	22,328	0
Visual-Motor Development in Infants at High Risk for Autism	R	93.242		K01MH109766-04	15,434	0
Visual-Motor Development in Infants at High Risk for Autism	R	93.242		K01MH109766-05	28,417	0
A Novel Framework for Impaired Imitation in ASD	R	93.242		R01 MH113652-04A	35,360	0
A Novel Framework for Impaired Imitation in ASD	R	93.242		R01 MH113652-04A-SUB	16,404	16,404
A Novel Framework for Impaired Imitation in ASD	R	93.242		R01 MH113652-05A	478,193	0
A Novel Framework for Impaired Imitation in ASD	R	93.242		R01 MH113652-05A-SUB	35,154	35,154
Behavioral and Neural Representations of Subjective Effort Cost	R	93.242		R01MH119086-01A1	126,055	0
Behavioral and Neural Representations of Subjective Effort Cost	R	93.242		R01MH119086-02	85,112	836
Behavioral and Neural Representations of Subjective Effort Cost	R	93.242		R01MH119086-03	211,553	2,637
Examinatin of Developmental Trajectories of Cognitive, Motor, & Emotional Control	R	93.242		R03MH119457-01A1	6,252	0
Examinatin of Developmental Trajectories of Cognitive, Motor, & Emotional Control	R	93.242		R03MH119457-01A1	33,321	0
Neurobiology of Social Behavior Circuit Analysis in Early Life	R	93.242		R00MH124434-03	177,927	0
Methyl-CpG-dependent transcription factor function in human glioma	R	93.853		R01NS091165-05	(12,449)	0
GABAergic Sensorimotor Dysfunction in Tourette Syndrome	R	93.853		R01NS096207-03	12,781	0
GABAergic Sensorimotor Dysfunction in Tourette Syndrome	R	93.853		R01NS096207-04	20,474	0
GABAergic Sensorimotor Dysfunction in Tourette Syndrome	R	93.853		R01NS096207-05	115,739	0
GABAergic Sensorimotor Dysfunction in Tourette Syndrome	R	93.853		R01NS096207-05 CAFFO SUI	721	721
GABAergic Sensorimotor Dysfunction in Tourette Syndrome	R	93.853		R01NS096207-05 EDDEN SUI	22,134	22,134
GABAergic Sensorimotor Dysfunction in Tourette Syndrome	R	93.853		R01NS096207-05 CINN SUB	168,528	168,528
Targeted Therapies for Neonatal White Matter Injury	R	93.853		R01NS097511-05	55,486	0
Targeted Therapies for Neonatal White Matter Injury	R	93.853		R01NS097511-05 SUB	13,301	13,301
Child Neurologist Career Development Program	R	93.853		K12NS098482-03 JHU SUB	(27,250)	0
Child Neurologist Career Development Program	R	93.853		K12NS098482-03 DUKE SUB	694	694
Child Neurologist Career Development Program	R	93.853		K12NS098482-03-JHU SUB	77,376	50,125
Child Neurologist Career Development Program	R	93.853		K12NS098482-04	324	0
Child Neurologist Career Development Program	R	93.853		K12NS098482-04-CORNELL SU	25,636	25,636
Child Neurologist Career Development Program	R	93.853		K12NS098482-04-STANFORD S	35,882	35,882
Child Neurologist Career Development Program	R	93.853		K12NS098482-04-BAYLOR SU	99,067	99,067
Child Neurologist Career Development Program	R	93.853		K12NS098482-04-JHU SUB	87,551	87,551
Child Neurologist Career Development Program	R	93.853		K12NS098482-04-MGH SUB	72,884	72,884
Child Neurologist Career Development Program	R	93.853		K12NS098482-04-WUSTL SUI	111,313	111,313
Child Neurologist Career Development Program	R	93.853		K12NS098482-04-U OF MICH S	25,530	25,530
Child Neurologist Career Development Program	R	93.853		K12NS098482-05	88,394	0
Child Neurologist Career Development Program	R	93.853		K12NS098482-05-CORNELL SU	20,771	20,771
Child Neurologist Career Development Program	R	93.853		K12NS098482-05-ELRICK SUI	68,996	0
Child Neurologist Career Development Program	R	93.853		K12NS098482-05-JHU SUB	77,779	77,779
Child Neurologist Career Development Program	R	93.853		K12NS098482-05-MGH SUB	107,455	107,455
Child Neurologist Career Development Program	R	93.853		K12NS098482-05-UCSF SUB	3,610	3,610
Child Neurologist Career Development Program	R	93.853		K12NS098482-05-LSJU SUB	4,932	4,932
Child Neurologist Career Development Program	R	93.853		K12NS098482-05-ROCHESTE	3,047	3,047
Child Neurologist Career Development Program	R	93.853		K12NS098482-05-U OF MICH S	110,723	110,723
Child Neurologist Career Development Program	R	93.853		K12NS098482-05-COLO SUB	46,589	46,589

The accompanying notes are an integral part of the schedule of expenditures of federal awards.

Kennedy Krieger Institute, Inc. and Affiliates
Schedule of Expenditures of Federal Awards
Year Ended June 30, 2022

Cluster/Federal Program	Entity	Assistance Listing Number	Pass Through Entity	Grant award number or pass-through entity identification number	Federal Expenditures	
					Total	Passed through to subrecipients
Child Neurologist Career Development Program	R	93.853		K12NS098482-05-STANFORD	\$ 96,489	\$ 96,489
Child Neurologist Career Development Program	R	93.853		K12NS098482-05-MGH SUB	85,129	85,129
Child Neurologist Career Development Program	R	93.853		K12NS098482-05-WUSTL KA	65,516	65,516
Child Neurologist Career Development Program	R	93.853		K12NS098482-05-OHSU RIDDL	94,861	94,861
Child Neurologist Career Development Program	R	93.853		K12NS098482-05-NCH-SETT	137,805	137,805
Child Neurologist Career Development Program	R	93.853		K12NS098482-05-COLO SUB	81,583	81,583
Child Neurologist Career Development Program	R	93.853		K12NS098482-06	75,135	0
Chromatin Modifications in GBM-Propagating Cells	R	93.853		R01NS096754-03A JHU SUB	15,080	15,080
Chromatin Modifications in GBM-Propagating Cells	R	93.853		R01NS096754-04A	1,747	292
Chromatin Modifications in GBM-Propagating Cells	R	93.853		R01NS096754-04A	8,637	8,637
Chromatin Modifications in GBM-Propagating Cells	R	93.853		R01NS096754-04A	15,098	15,098
Chromatin Modifications in GBM-Propagating Cells	R	93.853		R01NS096754-04A	212,196	0
Targeting Hyaluronan-Mediated Motility Receptor in Glioblastoma Stem Cells	R	93.853		R01NS099460-02	(501)	0
Targeting Hyaluronan-Mediated Motility Receptor in Glioblastoma Stem Cells	R	93.853		R01NS099460-03	9,020	0
Targeting Hyaluronan-Mediated Motility Receptor in Glioblastoma Stem Cells	R	93.853		R01NS099460-04	108,728	0
Targeting Hyaluronan-Mediated Motility Receptor in Glioblastoma Stem Cells	R	93.853		R01NS099460-05	237,233	0
Targeting Hyaluronan-Mediated Motility Receptor in Glioblastoma Stem Cells	R	93.853		R01NS099460-05 ZHOU SUB	23,112	23,112
Targeting TAZ-driven Oncogenic Signaling in Medulloblastoma	R	93.853		R21NS106407-01	(1,002)	0
Targeting TAZ-driven Oncogenic Signaling in Medulloblastoma	R	93.853		R21NS106407-02	(64)	0
Imaging Small Blood and Lymphahtic Vessel Abnormalities	R	93.853		R01NS108452-02	15,312	0
Imaging Small Blood and Lymphahtic Vessel Abnormalities	R	93.853		R01NS108452-02 SUPP	14,278	14,278
Imaging Small Blood and Lymphahtic Vessel Abnormalities	R	93.853		R01NS108452-02 JHU SUB	9,819	9,819
Imaging Small Blood and Lymphahtic Vessel Abnormalities	R	93.853		R01NS108452-03	211,660	0
Imaging Small Blood and Lymphahtic Vessel Abnormalities	R	93.853		R01NS108452-03 JHU SUB	77,824	77,824
Imaging Small Blood and Lymphahtic Vessel Abnormalities	R	93.853		R01NS108452-04	221,538	0
Imaging Small Blood and Lymphahtic Vessel Abnormalities	R	93.853		R01NS108452-04 JHU SUB	34,023	34,023
Imaging Small Blood and Lymphahtic Vessel Abnormalities	R	93.853		R01NS108452-04	8,092	0
Cerebrovascular Abnormalities in Huntingtons Disease	R	93.853		R21NS104480-02A1	(25,848)	0
Paracrine Angiotensin II Signaling Promotes Medulloblastoma	R	93.853		R21NS101400-01A1	(1,383)	0
Paracrine Angiotensin II Signaling Promotes Medulloblastoma	R	93.853		R21NS101400-02A1	29,885	20,172
Cortical Functional Connectivity as an Early Biomarker of Recovery in SCI	R	93.853		R21NS104644-02	23,380	0
Cortical Functional Connectivity as an Early Biomarker of Recovery in SCI	R	93.853		R21NS104644-02S1	24,013	0
Tet2 Regulation and Function in Glioma Cell Phenotype Reprogramming	R	93.853		R01NS110087-01A	(5,057)	0
Tet2 Regulation and Function in Glioma Cell Phenotype Reprogramming	R	93.853		R01NS110087-02A	58,658	0
Tet2 Regulation and Function in Glioma Cell Phenotype Reprogramming	R	93.853		R01NS110087-03A	269,107	0
Tet2 Regulation and Function in Glioma Cell Phenotype Reprogramming	R	93.853		R01NS110087-04A	14,164	0
Bioenergetic Failure Underlies Cerebral Dysmaturity After Perinatal Brain Injury	R	93.853		R01NS099461-05	255,715	0
Bioenergetic Failure Underlies Cerebral Dysmaturity After Perinatal Brain Injury	R	93.853		R01NS099461-05	48,126	0
Molecular Determinanats of Cellular Heteroenity and Theapeutic Resistance in GBM	R	93.853		R01NS120949-01	201,879	0
Molecular Determinanats of Cellular Heteroenity and Theapeutic Resistance in GBM	R	93.853		R01NS120949-01 SUB	27,742	27,742
Molecular Determinanats of Cellular Heteroenity and Theapeutic Resistance in GBM	R	93.853		R01NS120949-02	78,595	0

The accompanying notes are an integral part of the schedule of expenditures of federal awards.

Kennedy Krieger Institute, Inc. and Affiliates
Schedule of Expenditures of Federal Awards
Year Ended June 30, 2022

Cluster/Federal Program	Entity	Assistance Listing Number	Pass Through Entity	Grant award number or pass-through entity identification number	Federal Expenditures	
					Total	Passed through to subrecipients
Development of Mechanisms Underlying Human Motor Learning	R	93.853		R35NS122266-01	\$ 328,530.0	\$ -
Development of Mechanisms Underlying Human Motor Learning	R	93.853		R35NS122266-01	38,459	38,459
Development of Mechanisms Underlying Human Motor Learning	R	93.853		R35NS122266-01	26,497	26,497
Development of Mechanisms Underlying Human Motor Learning	R	93.853		R35NS122266-01	1,822	1,822
Development of Mechanisms Underlying Human Motor Learning	R	93.853		R35NS122266-01	70,897	0
Modeling Host Susceptibility Factors in Acute Flaccid Myelitis	R	93.853		R03NS118061-02	29,224	0
Extramural Research Programs in the Neurosciences Disorders	R	93.853		R01NS127280-01	52,144	0
Analysis of DARS2 in Leukoencephalopathy with Brainstem	R	93.853		R21NS125059-01	4,949	0
Noninvasive Prediction of Tumor Response to Gemcitabine using MRI	R	93.394		R01CA211087-03A	(10,051)	0
Noninvasive Prediction of Tumor Response to Gemcitabine using MRI	R	93.394		R01CA211087-04A	105,094	0
Leveraging energetics to Improve Gait Rehabilitation after Stroke	R	93.866		R21 AG059184-02A1	(14,947)	0
Impaired Cerebral Glucose Uptake in the Brain as an MRI marker for Alzheimer's Disease	R	93.866		R21 AG065794-01	(21,340)	0
Impaired Cerebral Glucose Uptake in the Brain as an MRI marker for Alzheimer's Disease	R	93.866		R21 AG065794-02	74,277	50,724
Contributions of Local Cerebral Iron to Cognitive Decline during Aging and Preclinical Alzheimer's Disease	R	93.866		R03 AG065527	6,604	0
Contributions of Local Cerebral Iron to Cognitive Decline during Aging and Preclinical Alzheimer's Disease	R	93.866		R03 AG065527	40,540	0
Advanced MR Imaging of Olfactory Impairment in Prodromal Alzheimers Disease	R	93.866		R01 AG064093-01	14,792	0
Advanced MR Imaging of Olfactory Impairment in Prodromal Alzheimers Disease	R	93.866		R01 AG064093-01	35,101	35,101
Advanced MR Imaging of Olfactory Impairment in Prodromal Alzheimers Disease	R	93.866		R01 AG064093-02	95,939	0
Advanced MR Imaging of Olfactory Impairment in Prodromal Alzheimers Disease	R	93.866		R01 AG064093-02	161,652	160,939
Advanced MR Imaging of Olfactory Impairment in Prodromal Alzheimers Disease	R	93.866		R01 AG064093-03	34,838	0
Altered pH in Early Alzheimers Disease Detected by Creatine	R	93.866		R21 AG074978-01	9,440	0
Developing MRI Contrast Agents to Detect Progression in Renal Disease	R	93.847		R01DK121847-01A1	144,998	0
Developing MRI Contrast Agents to Detect Progression in Renal Disease	R	93.847		R01DK121847-01A1	2,185	0
Developing MRI Contrast Agents to Detect Progression in Renal Disease	R	93.847		R01DK121847-01A1	405	0
Developing MRI Contrast Agents to Detect Progression in Renal Disease	R	93.847		R01DK121847-02A1	36,153	0
Developing MRI Contrast Agents to Detect Progression in Renal Disease	R	93.847		R01DK121847-02A1	4,539	4,539
Developing MRI Contrast Agents to Detect Progression in Renal Disease	R	93.847		R01DK121847-02A1	6,895	6,895
Developing MRI Contrast Agents to Detect Progression in Renal Disease	R	93.847		R01DK121847-03A1	108,970	0
Behavioral Health Workforce Education and Training Program	R	93.732		M01HP41974-01-01	35,290	0
Magnetic Particle Imaging Scanner	R	93.351		S10OD026740-01	180,000	0
Administration For Community Living						
Covid-19: Expanding Disabilities Networks Access to COVID 19 Vaccines	R	93.632		90DDC50061	36,499	0
The Health Resources and Services Administration						
MCH RESEARCH	R	93.110		T16MC29832-06	125,593	0
MCH RESEARCH	R	93.110		T16MC29832-07	24,534	0
Center for Mental Health Services						
Collective for Antiracist Child and Family Systems	R	93.243		H79SM085056-01	288,431	94,510
Office of the Secretary						
EMURG for Health Equity Leaders Fellowship Program	R	93.137		CPIMP211323-01	161,017	0
Total Department of Health and Human Services					18,038,690	3,241,972

The accompanying notes are an integral part of the schedule of expenditures of federal awards.

Kennedy Krieger Institute, Inc. and Affiliates

Schedule of Expenditures of Federal Awards

Year Ended June 30, 2022

Cluster/Federal Program	Entity	Assistance Listing Number	Pass Through Entity	Grant award number or pass-through entity identification number	Total	Passed through to subrecipients
Department of Defense						
US Army Medical Research						
Neurovascular Changes Associated with Olfactory Deficits in Early Parkinson's Disease	R	12.420		W81XWH017-PRP-FIA	\$ 4,843	\$ -
Alzheimers Research Program	R	12.420		W81XWH1810797	(23,936)	
Alzheimers Research Program	R	12.420		W81XWH1810797	44,602	44,602
Randomized Trial of Telehealth Parent-Implemented Intervention	R	12.420		W81XWH2110230	549,137	-
Randomized Trial of Telehealth Parent-Implemented Intervention	R	12.420		W81XWH2110232	59,673	-
Total Department of Defense					634,319	44,602
National Science Foundation						
Multimodal Algorithms for Notor Imitation Assesment in Autism	R	47.070		2124276	108,931	-
Total Research and Development - Direct Awards					18,781,940	3,286,574
Research and Development Cluster- Pass Through Awards						
Department of Health and Human Services						
Mental Health Research						
Somatossensory Inhibitory Dysfunction in Austism Spectrum Disorder	R	93.242	Johns Hopkins University	2003046760	5,396	0
Somatossensory Inhibitory Dysfunction in Austism Spectrum Disorder	R	93.242	Johns Hopkins University	2003046760	90,287	0
Feasibility, Acceptability, and Preliminary Efficacy of Text4Father for Improving Infant & Family Health	R	93.242	Johns Hopkins University	2004623345	1,241	0
Investigation of Cerebular Involvement in Cognitive Function	R	93.242	Johns Hopkins University	2002590758	1,909	0
Neural Mechanisms of HIV Associates CNS Dysfunction	R	93.242	Johns Hopkins University	2004497820	109,706	0
Brain Glutomine Metabolism in Schizophrenia	R	93.242	Johns Hopkins University	2005258964	5,540	0
Visual Hallucinations & Memory Impairment in Parkinson's Disease	R	93.242	Johns Hopkins University	2005277849	36,572	0
National Institute of Health						
Developing plans for a Baltimore site if the HEALTHy BCD study	R	93.279	Johns Hopkins University	2004576594	89,058	0
Drug Abuse & Addiction Research Program	R	93.279	Johns Hopkins University	2003097253	1,094	0
Healthy Brain & Child Development National Consortium	R	93.279	Johns Hopkins University	2005323012	222,078	0
Amide Proton Transfer MRI of Brain Tumors at 3T	R	93.394	Johns Hopkins University	2004159420	2,828	0
Amide Proton Transfer MRI of Brain Tumors at 3T	R	93.394	Johns Hopkins University	2004159420	7,676	0
Amide Proton Transfer MRI of Brain Tumors at 3T	R	93.394	Johns Hopkins University	2004159420	69,620	0
Highly Accelerated Chemical Exchange Saturation Transfer MRI Using Compressed Sensing	R	93.394	Johns Hopkins University	2004334298	(7,296)	0
A Wireless Multi-Function Microscope for Lifetime Imaging of the Brain Tumor Vasculome	R	93.394	Johns Hopkins University	2004637973	(1,101)	0
A Wireless Multi-Function Microscope for Lifetime Imaging of the Brain Tumor Vasculome	R	93.394	Johns Hopkins University	2004637973	14,477	0
Quantitative CEST MRI for GBM Ealry Response Prediction and Biopsy Guidance	R	93.394	Johns Hopkins University	2005008457	94,001	0
Precision Magnetic Hyperthermia by Integrating Magnetic Particle	R	93.394	Johns Hopkins University	2005219037	19,026	0
Computational Assessment of Galectin-3 Significance in Heart Failure	R	93.837	Johns Hopkins University	2003534038	78,942	0
Functional & Molecular Properties of PAX7	R	93.846	Johns Hopkins University	2003341654	(4,226)	0
Imaging Neurodegeneration in MS	R	93.853	Johns Hopkins University	2003795776	3,919	0
Imaging Neurodegeneration in MS	R	93.853	Johns Hopkins University	2003795776	128,191	0
Imaging Neurodegeneration in MS	R	93.853	Johns Hopkins University	2003795776	20,979	0
Development of Dendrimer N Acctylcysteine for the Treatment of Neonatal Brain Injury	R	93.853	Johns Hopkins University	2004023957	10,608	0
Development of Dendrimer N Acctylcysteine for the Treatment of Neonatal Brain Injury	R	93.853	Johns Hopkins University	2004023957	145	0
Development of MRI Microvascular Biomarkers in Cognitive Impairment and Dementia	R	93.853	Johns Hopkins University	2003986087	9,024	0
Development of MRI Microvascular Biomarkers in Cognitive Impairment and Dementia	R	93.853	Johns Hopkins University	2003986087	30,958	0

The accompanying notes are an integral part of the schedule of expenditures of federal awards.

Kennedy Krieger Institute, Inc. and Affiliates

Schedule of Expenditures of Federal Awards

Year Ended June 30, 2022

Cluster/Federal Program	Entity	Assistance Listing Number	Pass Through Entity	Grant award number or pass-through entity identification number	Federal Expenditures	
					Total	Passed through to subrecipients
Lymphocyte CpG Methylation Changes and Brain Pathology in Restless Leg Syndrome	R	93.853	Johns Hopkins University	2004063802	\$ 16,120	\$ -
Lymphocyte CpG Methylation Changes and Brain Pathology in Restless Leg Syndrome	R	93.853	Johns Hopkins University	2004063802	36,509	0
Lymphocyte CpG Methylation Changes and Brain Pathology in Restless Leg Syndrome	R	93.853	Johns Hopkins University	2004063802	1,701	0
Targeted Therapies for Rett Syndrome	R	93.853	Johns Hopkins University	2004344161	(4,616)	0
MOVE - Modeling of Fast Movement for Enhancement via Neuroprosthetics	R	93.853	Johns Hopkins University	2004347342	14,572	0
Imaging Brain Glucose Uptake by in VDMP MRI in Huntington's Disease	R	93.853	Johns Hopkins University	2004799501	63,977	0
Preclinical Stroke Trial with the PARP Inhibitor Veliparib	R	93.853	Johns Hopkins University	2004854058	17,805	0
Preclinical Stroke Trial with the PARP Inhibitor Veliparib	R	93.853	Johns Hopkins University	2004854058	89,084	0
Development of Novel Functional Markers for TBI Using Molecular MRI	R	93.853	Johns Hopkins University	2004868799	76,001	0
Development of Novel Functional Markers for TBI Using Molecular MRI	R	93.853	Johns Hopkins University	2004868799	32,478	0
Biomarkers of Brain Injury in Critically Ill Children on Extracorporeal Membrane Oxygenation ECMO	R	93.853	Johns Hopkins University	2005010377	10,411	0
Biomarkers of Brain Injury in Critically Ill Children on Extracorporeal Membrane Oxygenation ECMO	R	93.853	Johns Hopkins University	2005010377	35,019	0
Trial Readiness in Cavernous Angiomas and Symtomatic Hemorrhage	R	93.853	Johns Hopkins University	2005069221	6,845	0
Advanced MRI Studies of Cerebrovascular & Lymphatic Abnormalities	R	93.853	Johns Hopkins University	2005096780	113,001	0
Advanced MRI Studies of Cerebrovascular & Lymphatic Abnormalities	R	93.853	Johns Hopkins University	2005096780	56,720	0
Extramural Research Programs in the Neuro Disorders	R	93.853	Johns Hopkins University	2005206503	22,113	0
Characterization & Validation of CVR as a Biomarker	R	93.853	Johns Hopkins University	2005230728	12,516	0
Advanced MRI Biomarkers in HD Mouse Models Translatable to Humans	R	93.853	Johns Hopkins University	2005283967	58,824	0
The Role of RanBP2 in the Pathogenesis of Acute Encephalopathy	R	93.853	Johns Hopkins University	2005418247	25,323	0
A Placebo Controlled Effectiveness in INPH Shunting Trial	R	93.853	Johns Hopkins University	2005434649	24,865	0
Adult Biomarkers in Neonatal Brain Injury	R	93.865	Johns Hopkins University	2003671299	11,855	0
Adult Biomarkers in Neonatal Brain Injury	R	93.865	Johns Hopkins University	2003671299	34,256	0
CSA as a Preventable Public Health Problem	R	93.865	Johns Hopkins University	2004209564	7,322	0
CSA as a Preventable Public Health Problem	R	93.865	Johns Hopkins University	2004209564	14,594	0
MRI Biosensors and Complementary DRUG Noncarriers for Effective Image Guided Drug Delivery	R	93.865	Johns Hopkins University	2004411797	5,097	0
Measuring Altered Glutathione in Children with Autism	R	93.865	Johns Hopkins University	2005040776	47,892	0
Measuring Altered Glutathione in Children with Autism	R	93.865	Johns Hopkins University	2005040776	95,983	0
Alzheimer's Disease Neuroimaging Initiative	R	93.866	Johns Hopkins University	2003373473	7,595	0
Longitudinal Molecular Imaging of Neuropathology	R	93.866	Johns Hopkins University	2003816131	15,384	0
Brain Oxygen Consumption as an MRI Biomarker	R	93.866	Johns Hopkins University	2003950256	12,184	0
Brain Oxygen Consumption as an MRI Biomarker	R	93.866	Johns Hopkins University	2003950256	73,181	0
Neural Network Connectivity of Financial Capacity in Mild Cognitive Impairment	R	93.866	Johns Hopkins University	2003527906	3,780	0
Early Onset AD Consortium - LEADS	R	93.866	Johns Hopkins University	2004394773	3,402	0
Phase II/III Trial for Slowing Progression in Mild Cognitive Impairment	R	93.866	Johns Hopkins University	2004141582	566	0
Phase II/III Trial for Slowing Progression in Mild Cognitive Impairment	R	93.866	Johns Hopkins University	2004141582	6,504	0
JH Alzheimer's Disease Research Center	R	93.866	Johns Hopkins University	2004738174	34,830	0
Contribution of Cerebral Iron Load to Elderly Individuals with High Risk for Alzheimers	R	93.866	Johns Hopkins University	2004811688	5,356	0
Contribution of Cerebral Iron Load to Elderly Individuals with High Risk for Alzheimers	R	93.866	Johns Hopkins University	2004811688	45,490	0
Contribution of Cerebral Iron Load to Elderly Individuals with High Risk for Alzheimers	R	93.866	Johns Hopkins University	2004811688	5,006	0
Developing Protein-based Biomarkers for Alzheimer's Disease	R	93.866	Johns Hopkins University	2004839016	17,148	0
Non-Contrast MR imaging of Blood-Brain-Barrier Permeability in Alzheimer's Disease	R	93.866	Johns Hopkins University	2004827086	21,546	0
Non-Contrast MR imaging of Blood-Brain-Barrier Permeability in Alzheimer's Disease	R	93.866	Johns Hopkins University	2004827086	40,994	0

The accompanying notes are an integral part of the schedule of expenditures of federal awards.

Kennedy Krieger Institute, Inc. and Affiliates

Schedule of Expenditures of Federal Awards

Year Ended June 30, 2022

Cluster/Federal Program	Entity	Assistance Listing Number	Pass Through Entity	Grant award number or pass-through entity identification number	Total	Passed through to subrecipients
Transcranial Direct Current Stimulation on Typical & Atypical Alzheimer's Disease	R	93.866	Johns Hopkins University	2004902841	\$ 24,098	\$ -
Transcranial Direct Current Stimulation on Typical & Atypical Alzheimer's Disease	R	93.866	Johns Hopkins University	2004902841	54,716	0
Contribution of Cerebral Iron Load to Elderly Individuals with High Risk for Alzheimers	R	93.866	Johns Hopkins University	2004149879	7,578	0
Biomarkers of Cognitive Decline Among Normal Individuals Towards a Comprehensive Neurometabolic Profile in Patients w/ Mild Cognitive Impairment	R	93.866	Johns Hopkins University	2004408174	116,397	0
Blood Brain Barrier Dysfunction in Alzheimers Disease	R	93.866	Johns Hopkins University	2005076442	26,366	0
Mechanism of Pathologic Tau Fibrils Neuron to Neuron Transmission	R	93.866	Johns Hopkins University	2005230799	19,755	0
Mechanism of Pathologic Tau Fibrils Neuron to Neuron Transmission	R	93.866	Johns Hopkins University	2005393633	32,329	0
Heterochronic Blood Exchange Inhibits Synucleinopathy	R	93.866	Johns Hopkins University	2005393633	4,365	0
Heterochronic Blood Exchange Inhibits Synucleinopathy	R	93.866	Johns Hopkins University	2005406023	32,328	0
Heterochronic Blood Exchange Inhibits Synucleinopathy	R	93.866	Johns Hopkins University	2005406023	4,210	0
Neurodegenerative and Neurodevelopmental Subcortical Shape Diff	R	93.286	Johns Hopkins University	2003386771	4,626	0
Simultaneous Hadamard Editing of GABA and Glutathione	R	93.286	Johns Hopkins University	2003385023	1,273	0
Simultaneous Hadamard Editing of GABA and Glutathione	R	93.286	Johns Hopkins University	2003385023	2,828	0
Simultaneous Hadamard Editing of GABA and Glutathione	R	93.286	Johns Hopkins University	2003385023	(1,555)	0
Resource for Molecular Imaging agents in Precision Medicine	R	93.286	Johns Hopkins University	2003638047	181,681	0
Multi-Voxel Spectral Editing at 3T	R	93.286	Johns Hopkins University	2004721588	6,521	0
Intracellular Self-Assembly of Theranostic Nanoparticles for Imaging	R	93.286	Johns Hopkins University	2005101724	81,525	0
Intracellular Self-Assembly of Theranostic Nanoparticles for Imaging	R	93.286	Johns Hopkins University	2005101724	35,686	0
Chemical Exchange Saturation Transfer MR Fingerprinting	R	93.286	Johns Hopkins University	2004344815	12,758	0
Investigating Air Pollution Effects on the Developing Brain and ASD	R	93.113	Johns Hopkins University	2003188501	4,830	0
Stress and Chronic Alcohol Interactions	R	93.273	Johns Hopkins University	2003325699	39,827	0
Gene Delivery Nanoparticles to Treat Glioblastoma	R	93.395	Johns Hopkins University	2004276542	94,390	0
Gene Delivery Nanoparticles to Treat Glioblastoma	R	93.395	Johns Hopkins University	2004276542	68,132	0
Image-Guided ComboTherapies for Radiotherapy Induced Neurocognitive	R	93.395	Johns Hopkins University	2005282025	42,959	0
Johns Hopkins Institute for Clinical Translational Research	R	93.350	Johns Hopkins University	2004382572	143,653	0
Johns Hopkins Institute for Clinical Translational Research	R	93.350	Johns Hopkins University	2004382572	3,261	0
Impact of Hypothalamic Gliosis on Appetite Regulation & Obesity Risk	R	93.847	Johns Hopkins University	2004422191	44,740	0
Dorsomedial Hypothalamic Signaling Pathways & Energy Balance	R	93.847	Johns Hopkins University	2004985625	1,134	0
Assessing Arrhythmic Risk in Adult Patients with Duchenne Muscular Dystrophy	R	12.420	Johns Hopkins University	2004925324	64,114	0
Mapping of Brain GABA Levels in Tuberous Sclerosis Complex Using High-Resolution Proton Imaging	R	12.420	Johns Hopkins University	2004851931	37,079	0
Identifying the Underlying Mechanisms of Persistent Neurologic Symptoms	R	12.420	Johns Hopkins University	2005058980	19,845	0
Pediatric Integrated Care Collaborative	R	93.243	Johns Hopkins University	2005117860	34,301	0
Research Related to Deafness & Communication Disorders	R	93.173	Johns Hopkins University	2005189055	4,390	0
Environmental Influences on Child Health Outcomes	R	93.310	Johns Hopkins University	2005241153	68,985	0
Non-Invasive Tracking of Genome-Corrected iPS Cells in ALS	R	93.310	Johns Hopkins University	2005305416	12,358	0
Non-Invasive Tracking of Genome-Corrected iPS Cells in ALS	R	93.397	Johns Hopkins University	2005712820	50,142	0
In Vivo Assessment of Meningeal Inflammation and it's Clinical Impact in MS	R	93.853	University of Maryland, Baltimore	1712	9,655	0
In Vivo Assessment of Meningeal Inflammation and it's Clinical Impact in MS	R	93.853	University of Maryland, Baltimore	1712	139,642	0
Biomarkers for Therapy of FSHD (U54)	R	93.865	University of Massachusetts	WA00764092/OSP2018147	(1,495)	0
Biomarkers for Therapy of FSHD (U54)	R	93.865	University of Massachusetts	WA00763696/OSP2018145	(561)	0
Biomarkers for Therapy of FSHD (U54)	R	93.865	University of Massachusetts	WA00763696/OSP2018145	(1,282)	0
Brittle Bone Disorders Consortium of the Rare Disease Clinical Network	R	93.846	Baylor University	U54AR068069	13,254	0
Brittle Bone Disorders Consortium of the Rare Disease Clinical Network	R	93.846	Baylor University	U54AR068069	70,991	0

The accompanying notes are an integral part of the schedule of expenditures of federal awards.

Kennedy Krieger Institute, Inc. and Affiliates

Schedule of Expenditures of Federal Awards

Year Ended June 30, 2022

Cluster/Federal Program	Entity	Assistance Listing Number	Pass Through Entity	Grant award number or pass-through entity identification number	Federal Expenditures	
					Total	Passed through to subrecipients
An ASF Enriched Risk ECHO Cohort	R	93.310	Drexel University	UG30D023342	\$ 80,756	\$ -
An ASF Enriched Risk ECHO Cohort	R	93.310	Drexel University	UG30D023342	128,644	0
Oxidative Stree and Bipolar Disorder Trajectories	R	93.242	Partners Healthcare	11614	4,572	0
Clinical Readiness to Solve Barriers to Drug Development in FSHD	R	93.853	University of Rochester	417259/URFAO:GR510743	12,450	0
Meaningful Outcomes & MultiSite Readiness for Clinical Trials in Juvenile Neuronal Ceroid Lipofuscinosis	R	93.853	University of Rochester	URFAO: GR530284	71,731	0
Meaningful Outcomes & MultiSite Readiness for Clinical Trials in Juvenile Neuronal Ceroid Lipofuscinosis	R	93.853	University of Rochester	URFAO: GR530285	(273)	0
Meaningful Outcomes & MultiSite Readiness for Clinical Trials in Juvenile Neuronal Ceroid Lipofuscinosis	R	93.853	University of Rochester	URFAO: GR530285	18,302	0
Non-Contrast Enhanced Peripheral MR Angiography	R	93.837	Case Western University	RES514359	3,064	0
The Role of Executve Functions in Reading and Remediation	R	93.865	Children's Hospital Medical Center	3100658971	22,540	0
The Role of Executve Functions in Reading and Remediation	R	93.865	Children's Hospital Medical Center	3100658971	11,262	0
The Global Leukodystrophy Initiative Clinical Trials Network	R	93.853	Children's Hospital of Philadelphia	3202060620	16,848	0
The Global Leukodystrophy Initiative Clinical Trials Network	R	93.853	Children's Hospital of Philadelphia	3202030620	(8,176)	0
The Global Leukodystrophy Initiative Clinical Trials Network	R	93.853	Children's Hospital of Philadelphia	3202060620	(18,618)	0
The Global Leukodystrophy Initiative Clinical Trials Network	R	93.853	Children's Hospital of Philadelphia	3202060620	38,871	17,231
The Global Leukodystrophy Initiative Clinical Trials Network	R	93.853	Children's Hospital of Philadelphia	3202030620	10,350	0
The Global Leukodystrophy Initiative Clinical Trials Network	R	93.853	Children's Hospital of Philadelphia	3202060620	39,932	0
The Global Leukodystrophy Initiative Clinical Trials Network	R	93.853	Children's Hospital of Philadelphia	3202060620	74,867	14,471
Utility of Advanced MRI & Wearable Technology to Identify LBSL	R	93.853	Children's Hospital of Philadelphia	3202030622	133,852	0
Social Adversities, Epigenetics and the Obesity Epidemic	R	93.307	North Carolina State University	2017-1593-01	79,970	0
Solving the MRI Motion Problem with Framewise Integrated Real Time MRI Monitoring Software	R	93.242	Nous Imaging	R44MH121276-sub5	47,752	0
Solving the MRI Motion Problem with Framewise Integrated Real Time MRI Monitoring Software	R	93.242	Nous Imaging	R44MH121276-sub5	22,479	0
Motion-Robust Brain MRI for Infants	R	93.242	Nous Imaging	R44MH124567-sub5	6,851	0
Motion-Robust Brain MRI for Infants	R	93.242	Nous Imaging	R44MH124567-sub5	72,888	0
Supporting the Health & Well-Being of Children with Intellectual & Developmental Disability during COVID	R	93.310	The Washington University	WU-21-213	69,734	0
WUIDDRC and KKI Safe Return to School	R	93.310	The Washington University	WU-21-378	1,032,043	145,139
WUIDDRC and KKI Safe Return to School	R	93.310	The Washington University	WU-21-378	18,202	0
Illuminating Brain Function during Imitation in Children with ASD	R	93.310	The Washington University	WU-22-0399	6,764	0
Center for Disease Control and Prevention						
Covid 19: Addressing COVID-19 Vaccine Access and Confidence Among People with Disabilites	R	93.421	Association of University Centers on Disabilities	6/21/8815	34,423	0
Centers for Autism & Developmental Disabilities Research	R	93.073	Johns Hopkins University	2001438612	(784)	0
Centers for Autism & Developmental Disabilities Research	R	93.073	Johns Hopkins University	2001438612	27,998	0
Study to Explore Early Development	R	93.073	Johns Hopkins University	2005355148	8,292	0
Substance Abuse and Mental Health Services Administration						
Family Informed Trauma Treatment CTR-FITT	R	93.243	University of Maryland, Baltimore	1701143	10,190	0
Family Informed Trauma Treatment CTR-FITT	R	93.243	University of Maryland, Baltimore	1701143	190	0

The accompanying notes are an integral part of the schedule of expenditures of federal awards.

Kennedy Krieger Institute, Inc. and Affiliates
Schedule of Expenditures of Federal Awards
Year Ended June 30, 2022

Cluster/Federal Program	Entity	Assistance Listing Number	Pass Through Entity	Grant award number or pass-through entity identification number	Federal Expenditures	
					Total	Passed through to subrecipients
Administration for Community Living						
Center for Dignity in Healthcare for People with Disabilities	R	93.631	Children's Hospital Medical Center	309541	\$ 26,919	\$ -
Center for Dignity in Healthcare for People with Disabilities	R	93.631	Children's Hospital Medical Center	309541	35,244	0
UT2 Autism Intervention Research	R	93.877	Association of University Centers on Disabilities	13-21-8840	19,812	0
UT2 Autism Intervention Research	R	93.877	Association of University Centers on Disabilities	13-21-8840	4,584	0
Development of an MRI Template & Neuroimaging Biomarkers	R	93.853	Thomas Jefferson University	080-30000-S38601	8,647	0
Residential Shelter Care & Fingerprinting Services	C	93.676	Lutheran Immigration & Refugee Service	358-21-00	244,478	0
Residential Shelter Care & Fingerprinting Services	C	93.676	Lutheran Immigration & Refugee Service	358-21-00	22,826	0
Reliable Sensor Technology-Based for Rehabilitation	R	93.865	Leland Stanford Junior University	62613290-153996	16,142	0
Reliable Sensor Technology-Based for Rehabilitation	R	93.865	Leland Stanford Junior University	62613290-153996	432	0
A Safety and Efficacy Study of AAVA-hAADC	R	93.853	Ohio State University	GR125074	23,115	0
Early Childhood Constraint Therapy for Sensory Impairment	R	93.865	Emory University	A574496	36,023	0
Total Department of Health and Human Services					6,387,902	176,841
National Science Foundation						
Discovering Network Structure in the Space of Group Level Functional Differences	R	47.041	Johns Hopkins University	2004042235	11,888	0
Pediatric Influence of Cooling Duration on Efficacy in Cardiac Arrest	R	93.837	University of Michigan	SUBK00014168	76,723	0
Total National Science Foundation					88,611	-
Department of Defense						
Uniformed Services University of the Health Sciences						
Reliable Sensor Technology-Based for Rehabilitation	R	12.750	Henry M. Jackson Foundation	5767-1025782	962,700	0
Total Research and Development Cluster - Pass Through Awards					7,439,213	176,841
Research and Development Cluster - Total Awards					26,221,153	3,463,415
Child Nutrition Cluster						
United States Department of Agriculture						
Food and Nutrition Service						
School Breakfast Program	C	10.553		9962	22,537	-
School Lunch Program	C	10.555		9962	71,513	-
Total Child Nutrition Cluster					94,050	-

The accompanying notes are an integral part of the schedule of expenditures of federal awards.

Kennedy Krieger Institute, Inc. and Affiliates

Schedule of Expenditures of Federal Awards

Year Ended June 30, 2022

Cluster/Federal Program	Entity	Assistance Listing Number	Pass Through Entity	Grant award number or pass-through entity identification number	Federal Expenditures	
					Total	Passed through to subrecipients
Special Education Cluster						
United States Department of Education						
Office of Special Education and Rehabilitative Services						
Providing Technical Assistance to the Eastern Shore of Maryland	R	84.027		200829	\$ 199,786	\$ -
State Grant - B - Kodem Kol	R	84.027		201838	12,000	-
Pact: World Of Care Child Care Center	P	84.173		180782	11,852	-
Pact: World Of Care Child Care Center	P	84.173		180540	1,033	-
Pact: World Of Care Child Care Center	P	84.173		190384	115,935	-
Pact: World Of Care Child Care Center	P	84.173		190384	12,665	-
Pact: Helping Children w/Special Needs Therapeutic Nursery -YMCA	P	84.173		190604	8,441	-
Pact: Helping Children w/Special Needs Therapeutic Nursery -YMCA	P	84.173		190604	1,523	-
Pact: Helping Children w/Special Needs Therapeutic Nursery -YMCA	P	84.173		190604	114,180	-
Pact: Helping Children w/Special Needs Therapeutic Nursery -YMCA	P	84.173		190604	11,639	-
Total Special Education Cluster					489,054	-
Head Start Cluster						
United States Department of Health and Human Services						
Administration for Children and Families						
Southeast Baltimore EHS	C	93.600	Maryland Family Network	362	3,688	-
Southeast Baltimore EHS	C	93.600	Maryland Family Network	362	11,883	-
PACT EHS Therapeutic Nursery	P	93.600	Maryland Family Network	3034	(576)	-
PACT EHS Therapeutic Nursery	P	93.600	Maryland Family Network	3034	(15)	-
PACT EHS Therapeutic Nursery	P	93.600	Maryland Family Network	3034	113,593	-
PACT EHS Therapeutic Nursery - COVID 19 Fund	P	93.600	Maryland Family Network	3034	8,503	-
PACT EHS Therapeutic Nursery	P	93.600	Maryland Family Network	3034	250,504	-
PACT EHS Therapeutic Nursery - COVID 19 Fund	P	93.600	Maryland Family Network	3034	47,921	-
Early Head Start Center	C	93.600	Maryland Family Network	650	33,751	-
Early Head Start Center	C	93.600	Maryland Family Network	650	399,195	-
Early Head Start Center	C	93.600	Maryland Family Network	650	397,816	-
Early Head Start Center	C	93.600	Maryland Family Network	650	5,816	-
Early Head Start Center	C	93.600	Maryland Family Network	650	12,168	-
Early Head Start Center	C	93.600	Maryland Family Network	650	637,861	-
Early Head Start Center	C	93.600	Maryland Family Network	650	684,723	-
Early Head Start Center	C	93.600	Maryland Family Network	650	431,405	-
Total Head Start Cluster					3,038,236	-
Child Care Development Fund Cluster						
Child Care Stabilization Funds American Rescue Plan	C	93.575		2101MDCSC6	61,000	-
Child Care Stabilization Funds American Rescue Plan	C	93.575		2101MDCSC6	27,000	-
Child Care Stabilization Funds American Rescue Plan	C	93.575		2101MDCSC6	53	-
Child Care Stabilization Funds American Rescue Plan	C	93.575		2101MDCSC6	28,500	-
Child Care Stabilization Funds American Rescue Plan	C	93.575		2101MDCSC6	321	-
Child Care Stabilization Funds American Rescue Plan	C	93.575		2101MDCSC6	13,032	-
Total Child Care Development Fund Cluster					129,906	-

The accompanying notes are an integral part of the schedule of expenditures of federal awards.

Kennedy Krieger Institute, Inc. and Affiliates

Schedule of Expenditures of Federal Awards

Year Ended June 30, 2022

Cluster/Federal Program	Entity	Assistance Listing Number	Pass Through Entity	Grant award number or pass-through entity identification number	Federal Expenditures	
					Total	Passed through to subrecipients
Other Sponsored Programs - Direct Awards						
Department of Health and Human Services						
Health Resources and Services Administration						
Children's Hospital Graduate Medical Education	H	93.255		338-002	\$ 387,713	\$ -
Total ALN 93.255					387,713	-
COVID-19: Provider Relief Fund and American Rescue Plan (ARP) Rural Distribution	H	93.498		P4 - 87251018177	5,000,000	-
COVID-19: Provider Relief Fund and American Rescue Plan (ARP) Rural Distribution	C	93.498		CR-04988473457	58,327	-
Total ALN 93.498					5,058,327	-
MCH Training Program in Neurodevelopment Disabilities	H	93.110		2 T73 MC17245-11-00	712,922	-
Total ALN 93.110					712,922	-
Administration for Community Living						
Developmental Disabilities	H	93.632		90DD0707/04	(49)	0
Developmental Disabilities	H	93.632		90DD0707/04	577,352	0
Total ALN 93.632					577,303	-
United States Department of Education						
Institute of Education Sciences						
Efficacy Trial of Early Achievements Comp Intervention Preschoolers with Autism	R	84.324A		R 324 A160228	355	-
Development of an Intervention for Center-Based Early Childhood Education	R	84.324A		R 324 A180085	124	-
Development of an Intervention for Center-Based Early Childhood Education	R	84.324A		R 324 A180085	460,945	-
Developing Early Achievements for Pre-K Children with Developmental Language Disorders	R	84.324A		R 324 A210031	193,836	-
Total ALN 84.324A					655,260	-
Covid-19: Coronavirus Response & Relief Supplemental Appropriations Act - GEER	H	84.425R			86,748	-
Total ALN 84.3425R					86,748	-
Federal Communications Commission						
COVID-19 - Telecommunications and Equipment	H	32.006		0043	(512)	-
Total ALN 32.006					(512)	-
Department of the Treasury						
Departmental Offices						
Covid-19: Providing Emergency Relief for Community Providers of Services to Individuals with Disabilities - COVID	H	21.027			12,363	-
2021 BALT NONPROFIT RELIEF FUN	H	21.027			10,000	-
Total ALN 21.027					22,363	-
Total Other Programs - Direct Awards					11,251,370	-

The accompanying notes are an integral part of the schedule of expenditures of federal awards.

Kennedy Krieger Institute, Inc. and Affiliates
Schedule of Expenditures of Federal Awards
Year Ended June 30, 2022

Cluster/Federal Program	Entity	Assistance Listing Number	Pass Through Entity	Grant award number or pass-through entity identification number	Federal Expenditures	
					Total	Passed through to subrecipients
Other Sponsored Programs - Pass Through Awards						
United States Department of Justice						
Office of Justice Programs						
Underserved Victims Project	C	16.575	Governor's Office Of Crime Prevention, Youth & Victim Services	1299	\$ 86,594	\$ -
Underserved Victims Project	C	16.575	Governor's Office Of Crime Prevention, Youth & Victim Services	1299	227,664	0
Total ALN 16.575					314,258	-
Maryland State Department of Education						
Baltimore City Infants & Toddlers Program	P	84.181A	Baltimore City	CO#38176	46,124	-
Baltimore City Infants & Toddlers Program	P	84.181A	Baltimore City	CO#38177	58,374	-
Baltimore City Infants & Toddlers Program	R	84.181A	Baltimore City	CO#37753	51,582	-
Total ALN 84.181A					156,080	-
Preschool Development	C	84.419	Governor's Office Of Crime Prevention, Youth & Victim Services	170362	(846)	-
Preschool Development	C	84.419	Governor's Office Of Crime Prevention, Youth & Victim Services	200630	59,095	-
Preschool Development	C	84.419	Governor's Office Of Crime Prevention, Youth & Victim Services	200630	311,236	-
Preschool Development	C	84.419	Governor's Office Of Crime Prevention, Youth & Victim Services	200630	250	-
Total ALN 84.419					369,735	-
Covid-19: Building School Psychologist's Knowledge, Skills, and Practice to Support Education - COVID	C	84.424A		211094	8,455	-
Total ALN 84.424A					8,455	-
Promoting Positive Outcomes for Infant & Toddlers	C	93.434		211283	(3,638)	-
Promoting Positive Outcomes for Infant & Toddlers	C	93.434		211283	205,716	-
Promoting Positive Outcomes for Infant & Toddlers	C	93.434		211283	81,563	-
Total ALN 93.434					283,641	-
United States Department of Health and Human Services						
Administration for Community Living						
Enhancing Advocacy & Public Policy Work Project	H	93.630	Maryland Developmental Disabilities Council	20-QA-01	62,618	-
Enhancing Advocacy & Public Policy Work Project	H	93.630	Maryland Developmental Disabilities Council	20-QA-01	81,476	-
Total ALN 93.630					144,094	-
Health Resources and Services Administration						
Genetics Laboratory	H	93.994	Maryland Department of Health	PHPA-G2084	38,329	-
Within My World	P	93.994	Maryland Department of Health	FH795CSN/PHPA-G-1165	(798)	-
Within My World	P	93.994	Maryland Department of Health	FH795CSN/PHPA-G-1165	399,842	-
Enhancing Child Care For Children	C	93.994	Maryland Department of Health	MR554 MFC	286	-
Enhancing Child Care For Children	C	93.994	Maryland Department of Health	MR554 MFC	125,530	-
Project STIR	C	93.994	Maryland Department of Health	DD964 ISS	137,425	-
Project STIR	C	93.994	Maryland Department of Health	DD964 ISS	124,050	-
Total ALN 93.994					824,664	-

The accompanying notes are an integral part of the schedule of expenditures of federal awards.

Kennedy Krieger Institute, Inc. and Affiliates
Schedule of Expenditures of Federal Awards
Year Ended June 30, 2022

Cluster/Federal Program	Entity	Assistance Listing Number	Pass Through Entity	Grant award number or pass-through entity identification number	Federal Expenditures	
					Total	Passed through to subrecipients
Baltimore Mental Health Systems						
Therapeutic Nursery	P	93.000		POS#40	\$ 200,691	\$ -
Therapeutic Nursery	P	93.000		POS#40	40,000	-
Total Baltimore Mental Health Systems					240,691	-
Total Other Programs - Pass Through Awards					2,341,618	-
Total Other Sponsored Programs					13,592,988	-
Total Federal Expenditures					39,814,141	3,463,415

The accompanying notes are an integral part of the schedule of expenditures of federal awards.

Kennedy Krieger Institute, Inc. and Affiliates
Notes to Schedule of Expenditures of Federal Awards
Year Ended June 30, 2022

Kennedy Krieger Institute, Inc. and Affiliates
Notes to Schedule of Expenditures of Federal Awards
Year Ended June 30, 2022

1. BASIS OF PRESENTATION

The accompanying Schedule of Expenditures of Federal Awards (the "Schedule") summarizes the expenditures of Kennedy Krieger Institute, Inc. and Affiliates (the "Institute") under programs of the Federal Government for the year ended June 30, 2022. The information presented in the Schedule

is presented on the accrual basis of accounting, which is in accordance with the Title 2 U.S. Code of Federal Regulations Part 200, Uniform Administrative Requirements, Cost Principles, and Audit Requirements for Federal Awards (Uniform Guidance). Expenditures for federal awards are determined using the cost principles set forth in the Uniform Guidance. Under these cost principles, certain types of expenditures are not allowable or are limited to reimbursement.

The accompanying Schedule includes the federal grant transactions of the Institute and includes Federal Awards made to the following corporate entities: Kennedy Krieger Children's Hospital, Inc., Hugo W. Moser Research Institute at Kennedy Krieger, Inc., Kennedy Krieger Education & Community Services, Inc. and PACT: Helping Children with Special Needs, Inc. under programs of the federal government for the year ended June 30, 2022. These corporate entities are denoted on the Schedule as follows:

	Total Federal Expenditures	Passed to Subrecipients	
R	\$ 26,872,477	\$ 3,463,415	<i>R – Hugo W. Moser Research Institute at Kennedy Krieger, Inc.</i>
C	4,531,273	-	<i>H – Kennedy Krieger Children's Hospital, Inc.</i>
P	1,441,431	-	<i>C – Kennedy Krieger Education & Community Services, Inc.</i>
H	6,968,960	-	<i>P – PACT: Helping Children with Special Needs, Inc.</i>
	<u>\$ 39,814,141</u>	<u>\$ 3,463,415</u>	

Because the Schedule presents only a selected portion of the operations of the Institute, it is not intended to and does not present the financial position, results of operations and non-operating activity, or cash flows of the Institute. Negative amounts reflect adjustments made to expenditures reported in prior years in the normal course of business.

For purposes of the Schedule, federal awards include all awards in the form of grants, contracts, and similar agreements entered into directly between the Institute and agencies and departments of the federal government, or non-federal pass-through entities. Federal Assistance Listing Numbers and pass-through identification numbers are included when available.

2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

The Schedule reflects federal award program expenditures recognized on the accrual basis of accounting in accordance with accounting principles generally accepted in the United States of America. The Institute has not elected to use the 10% de minimis rate for indirect costs. Indirect costs are billed based upon negotiated and budgeted rates.

Kennedy Krieger Institute, Inc. and Affiliates
Notes to Schedule of Expenditures of Federal Awards
Year Ended June 30, 2022

3. DEPARTMENT OF HEALTH AND HUMAN SERVICES – PROVIDER RELIEF FUNDS

The Schedule includes grant activity related to the Department of Health and Human Services (“HHS”) Provider Relief Fund and American Rescue Plan (ARP) Distribution Assistance Listing Number 93.498. As required based on guidance in the 2022 OMB Compliance Supplement, the Schedule includes all Period 2 funds received between July 1, 2020 to December 31, 2020 and expended by December 31, 2021 as reported to HRSA via the PRF Reporting Portal. The Schedule thus includes \$1,560,903 of direct expenditures and \$3,497,424 in lost revenue. Lost revenue does not represent an expenditure in the Institutes financial statements and thus is a reconciling item between the federal expenses in the financial statements and the amount included on the Schedule.

Part II
Reports` on Compliance and Internal Control



Report of Independent Auditors on Internal Control Over Financial Reporting and on Compliance and Other Matters Based on an Audit of Financial Statements Performed in Accordance with Government Auditing Standards

To the Board of Directors of Kennedy Krieger Institute, Inc. and Affiliates

We have audited, in accordance with auditing standards generally accepted in the United States of America and the standards applicable to financial audits contained in *Government Auditing Standards*, issued by the Comptroller General of the United States, the consolidated financial statements of Kennedy Krieger Institute, Inc. and Affiliates (the "Institute"), which comprise the consolidated balance sheet as of June 30, 2022, and the related consolidated statements of operations and changes in net assets and cash flows for the year then ended, and the related notes to the financial statements, and have issued our report thereon dated October 14, 2022.

Internal Control Over Financial Reporting

In planning and performing our audit of the financial statements, we considered the Institute's internal control over financial reporting ("internal control") as a basis for designing the audit procedures that are appropriate in the circumstances for the purpose of expressing our opinion on the financial statements, but not for the purpose of expressing an opinion on the effectiveness of the Institute's internal control. Accordingly, we do not express an opinion on the effectiveness of the Institute's internal control.

A *deficiency in internal control* exists when the design or operation of a control does not allow management or employees, in the normal course of performing their assigned functions, to prevent, or detect and correct, misstatements on a timely basis. A *material weakness* is a deficiency, or a combination of deficiencies, in internal control such that there is a reasonable possibility that a material misstatement of the entity's financial statements will not be prevented, or detected and corrected on a timely basis. A *significant deficiency* is a deficiency, or a combination of deficiencies, in internal control that is less severe than a material weakness, yet important enough to merit attention by those charged with governance.

Our consideration of internal control was for the limited purpose described in the first paragraph of this section and was not designed to identify all deficiencies in internal control that might be material weaknesses or significant deficiencies. Given these limitations, during our audit we did not identify any deficiencies in internal control that we consider to be material weaknesses. However, material weaknesses or significant deficiencies may exist that were not identified.

Report on Compliance and Other Matters

As part of obtaining reasonable assurance about whether the Institute's consolidated financial statements are free from material misstatement, we performed tests of its compliance with certain provisions of laws, regulations, contracts and grant agreements, noncompliance with which could have a direct and material effect on the financial statements. However, providing an opinion on compliance with those provisions was not an objective of our audit, and accordingly, we do not express such an opinion. The results of our tests disclosed no instances of noncompliance or other matters that are required to be reported under *Government Auditing Standards*.



Purpose of this Report

The purpose of this report is solely to describe the scope of our testing of internal control and compliance and the results of that testing, and not to provide an opinion on the effectiveness of the entity's internal control or on compliance. This report is an integral part of an audit performed in accordance with *Government Auditing Standards* in considering the entity's internal control and compliance.

Accordingly, this communication is not suitable for any other purpose.

PricewaterhouseCoopers LLP

Baltimore, Maryland
October 14, 2022



Report of Independent Auditors on Compliance for Each Major Program and on Internal Control Over Compliance Required by Uniform Guidance

To the Board of Directors of Kennedy Krieger Institute, Inc. and Affiliates

Report on Compliance for Each Major Federal Program

Opinion on Each Major Federal Program

We have audited Kennedy Krieger Institute Inc.'s and Affiliates (the "Institute") compliance with the types of compliance requirements identified as subject to audit in the *OMB Compliance Supplement* that could have a direct and material effect on each of the Institute's major federal programs for the year ended June 30, 2022. The Institute's major federal programs are identified in the summary of auditor's results section of the accompanying schedule of findings and questioned costs.

In our opinion, the Institute complied, in all material respects, with the types of compliance requirements referred to above that could have a direct and material effect on each of its major federal programs for the year ended June 30, 2022.

Basis for Opinion on Each Major Federal Program

We conducted our audit of compliance in accordance with auditing standards generally accepted in the United States of America (US GAAS); the standards applicable to financial audits contained in Government Auditing Standards issued by the Comptroller General of the United States; and the audit requirements of Title 2 U.S. Code of Federal Regulations Part 200, Uniform Administrative Requirements, Cost Principles, and Audit Requirements for Federal Awards (Uniform Guidance). Our responsibilities under those standards and the Uniform Guidance are further described in the Auditors' Responsibilities for the Audit of Compliance section of our report.

We are required to be independent of the Institute and to meet our other ethical responsibilities, in accordance with relevant ethical requirements relating to our audit. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion on compliance for each major federal program. Our audit does not provide a legal determination of Institute's compliance with the compliance requirements referred to above.

Responsibilities of Management for Compliance

Management is responsible for compliance with the requirements referred to above and for the design, implementation, and maintenance of effective internal control over compliance with the requirements of laws, statutes, regulations, rules and provisions of contracts or grant agreements applicable to Institute's federal programs.



Auditors' Responsibilities for the Audit of Compliance

Our objectives are to obtain reasonable assurance about whether material noncompliance with the compliance requirements referred to above occurred, whether due to fraud or error, and express an opinion on the Institute's compliance based on our audit. Reasonable assurance is a high level of assurance but is not absolute assurance and therefore is not a guarantee that an audit conducted in accordance with US GAAS, Government Auditing Standards, and the Uniform Guidance will always detect material noncompliance when it exists. The risk of not detecting material noncompliance resulting from fraud is higher than for that resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control. Noncompliance with the compliance requirements referred to above is considered material, if there is a substantial likelihood that, individually or in the aggregate, it would influence the judgment made by a reasonable user of the report on compliance about the Institute's compliance with the requirements of each major federal program as a whole.

In performing an audit in accordance with US GAAS, Government Auditing Standards, and the Uniform Guidance, we:

- Exercise professional judgment and maintain professional skepticism throughout the audit.
- Identify and assess the risks of material noncompliance, whether due to fraud or error, and design and perform audit procedures responsive to those risks. Such procedures include examining, on a test basis, evidence regarding the Institute's compliance with the compliance requirements referred to above and performing such other procedures as we considered necessary in the circumstances.
- Obtain an understanding of the Institute's internal control over compliance relevant to the audit in order to design audit procedures that are appropriate in the circumstances and to test and report on internal control over compliance in accordance with the Uniform Guidance, but not for the purpose of expressing an opinion on the effectiveness of the Institute's internal control over compliance. Accordingly, no such opinion is expressed.

We are required to communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and any significant deficiencies and material weaknesses in internal control over compliance that we identified during the audit.

Other Matters

The results of our auditing procedures disclosed instances of noncompliance, which are required to be reported in accordance with the Uniform Guidance and which are described in the accompanying schedule of findings and questioned costs as item 2022-001. Our opinion on each major federal program is not modified with respect to these matters.

The Institute's response to the noncompliance findings identified in our audit is described in the accompanying corrective action plan. The Institute's response was not subjected to the other auditing procedures applied in the audit of compliance and, accordingly, we express no opinion on the response.



Report on Internal Control Over Compliance

A *deficiency in internal control over compliance* exists when the design or operation of a control over compliance does not allow management or employees, in the normal course of performing their assigned functions, to prevent, or detect and correct, noncompliance with a type of compliance requirement of a federal program on a timely basis. A *material weakness in internal control over compliance* is a deficiency, or combination of deficiencies, in internal control over compliance, such that there is a reasonable possibility that material noncompliance with a type of compliance requirement of a federal program will not be prevented, or detected and corrected, on a timely basis. A *significant deficiency in internal control over compliance* is a deficiency, or a combination of deficiencies, in internal control over compliance with a type of compliance requirement of a federal program that is less severe than a material weakness in internal control over compliance, yet important enough to merit attention by those charged with governance.

Our consideration of internal control over compliance was for the limited purpose described in the Auditors' Responsibilities for the Audit of Compliance section above and was not designed to identify all deficiencies in internal control over compliance that might be material weaknesses or significant deficiencies in internal control over compliance. Given these limitations, during our audit we did not identify any deficiencies in internal control over compliance that we consider to be material weaknesses, as defined above. However, material weaknesses or significant deficiencies in internal control over compliance may exist that were not identified.

Our audit was not designed for the purpose of expressing an opinion on the effectiveness of internal control over compliance. Accordingly, no such opinion is expressed.

The purpose of this report on internal control over compliance is solely to describe the scope of our testing of internal control over compliance and the results of that testing based on the requirements of the Uniform Guidance. Accordingly, this report is not suitable for any other purpose.

PricewaterhouseCoopers LLP

Baltimore, Maryland
March 20, 2023

Part III
Schedule of Findings and Questioned Costs

Kennedy Krieger Institute, Inc. and Affiliates
Schedule of Findings and Questioned Costs
Year Ended June 30, 2022

I. Summary of Auditor's Results

Financial Statements

Type of auditor's report issued on whether the financial statements audited were prepared in accordance with GAAP Unmodified

Internal control over financial reporting:

1. Material weakness(es) identified? No

2. Significant deficiency(ies) identified? None Reported

Noncompliance material to financial statements noted? No

Federal Awards

Internal control over major federal programs:

1. Material weakness(es) identified? No

2. Significant deficiency(ies) identified? None Reported

Type of auditor's report issued on compliance for major federal programs: Unmodified

Any audit findings disclosed that are required to be reported in accordance with 2 CFR 200.516(a)? Yes

Identification of major federal programs:

Assistance Listing Number(s)	Name of Federal Program/Cluster
93.600	Head Start Custer
93.498	COVID-19: Provider Relief Fund and American Rescue Plan (ARP) Rural Distribution
16.575	Underserved Victims Project

Dollar threshold used to distinguish between type A and type B programs:

\$1,194,424

Auditee qualified as a low-risk auditee? Yes

Kennedy Krieger Institute, Inc. and Affiliates

Schedule of Findings and Questioned Costs

Year Ended June 30, 2022

II. Financial Statement Findings

There were no matters reported

III. Federal Award Findings and Questioned Costs

2022-001: Lost Revenues Reporting Methodology

Cluster: Not applicable

Federal Granting Agency: Health Resources and Services Administration

Award Name: COVID-19 Provider Relief Fund and American Rescue Plan (ARP) Rural Distribution – Period 2

Assistance Listing #: 93.498

Assistance Listing Title: COVID-19 Provider Relief Fund and American Rescue Plan (ARP) Rural Distribution – Period 2

Award Year: January 1, 2020 – June 30, 2022

Criteria

Step Six of the Steps on Reporting on Use of Funds section of the June 11, 2021 Provider Relief Fund (PRF) General and Targeted Distribution Post-Payment Notice of Reporting Requirements requires recipients that apply PRF payments toward lost revenues to use one of the following three options for calculating lost revenues:

- Option (i): difference between actual patient care revenues;
- Option (ii): difference between budgeted (prior to March 27, 2020) and actual patient care revenues; or
- Option (iii): calculated by any reasonable method of estimating revenues

Condition

The Company calculated the portion of its Period 2 PRF payments applied toward lost revenues using Option (iii); however, the Company completed its Period 2 PRF Reporting Portal submissions and attested to calculating lost revenues using Option (i).

Cause

The Company did not interpret the HRSA PRF Reporting instructions correctly therefore attested to using Option (i) in its Period 2 PRF Reporting Portal submissions.

Effect

The Company incorrectly attested to the methodology utilized to calculate lost revenue in accordance with the June 11, 2021 PRF General and Targeted Distribution Post-Payment Notice of Reporting Requirements. In addition, as required by the Health Resources & Services Administrator (HRSA) when Option (iii) is utilized, information used to support the methodology used was not provided to HRSA when the portal reporting was submitted. This is a repeat finding from the prior year.

Questioned Costs

None noted.

Kennedy Krieger Institute, Inc. and Affiliates
Schedule of Findings and Questioned Costs
Year Ended June 30, 2022

Recommendation

We recommend the Company contact the Health Resources & Services Administrator (HRSA) to determine any required corrective actions related to the incorrect reporting.

Management's Views and Corrective Action Plan

Management's response is included in "Management's Views and Corrective Action Plan" included at the end of this report.

Kennedy Krieger Institute, Inc. and Affiliates
Schedule of Prior Audit Findings and Status
Year Ended June 30, 2022

III. Federal Award Findings and Questioned Costs

2021-001: Lost Revenues

Reporting Methodology:

Cluster: Not applicable

Federal Granting Agency: Health Resources and Services Administration

Award Name: COVID-19 Provider Relief Fund and American Rescue Plan (ARP) Rural Distribution – Period 1

Assistance Listing #: 93.498

Assistance Listing Title: COVID-19 Provider Relief Fund and American Rescue Plan (ARP) Rural Distribution – Period 1

Award Year: January 1, 2020 – June 30, 2021

Criteria

Step Six of the Steps on Reporting on Use of Funds section of the June 11, 2021 Provider Relief Fund (PRF) General and Targeted Distribution Post-Payment Notice of Reporting Requirements requires recipients that apply PRF payments toward lost revenues to use one of the following three options for calculating lost revenues:

- Option (i): difference between actual patientcare revenues;
- Option (ii): difference between budgeted (prior to March 27, 2020) and actual patient care revenues; or
- Option (iii): calculated by any reasonable method of estimating revenues

Condition

The Company calculated the portion of its Period 1 PRF payments applied toward lost revenues using Option (iii); however, the Company completed its Period 1 PRF Reporting Portal submissions and attested to calculating lost revenues using Option (i).

Refer to current year finding 2022-1.



Finance

March 20, 2023

Management's Views and Corrective Action Plan:

Finding 2022-001: Provider Relief Fund Lost Revenue Reporting Methodology for Kennedy Krieger Children's Hospital

In attesting to the methodology used to calculate lost revenue in accordance with the June 11, 2021 General and Targeted Distribution Post-Payment Notice of Reporting Requirements, Option (i) difference between actual patient care revenues was selected in the HRSA reporting portal. Differences in actual patient care revenues were used in both the base and target periods, however, we made a modification to what was included in patient care revenue and only included those revenues generated through inpatient services and excluded patient care revenue generated from outpatient services. The rationale for including inpatient revenue and excluding outpatient revenue is detailed below.

The pandemic impacted patient service revenue on the inpatient units by contributing to lower inpatient census for a variety of reasons. These reasons include mandatory infection control, patient distancing and isolation requirements and severe staffing shortages. All of our semi-private and other multi-patient rooms were converted to private rooms to limit patient contact with other patients and their families during admission. Additionally, we only permitted patient admissions from Maryland and our neighboring states (State mandates), thereby limiting the patient admission pool. Last, the pandemic created severe staffing shortages in nursing, therapy and clinical aids thereby requiring reduced admissions for patient safety reasons. The shortages occurred due staff COVID infection, exposure, isolation and other limitations on their ability to perform their jobs. These factors drove down inpatient admissions, patient days and the related patient service revenue levels as compared to pre-pandemic levels.


At the outset of the pandemic, outpatient operations were essentially shut down with very few patients seen. However, within 2 to 4 weeks from pandemic outset, we were able to effectively pivot operations from a completely on-site operation to providing services to more than 20,000 outpatient visits through tele-health. Using tele-health, patients were able to see their clinical providers from their home via a Zoom link. Same was true for the clinical providers. The quick transition to tele-health really limited the impact that the pandemic had on outpatient operations and specifically limited lost revenue to only a couple weeks. The quick change in the method of care delivery between on-site services and services rendered by telehealth had a significant impact on provider productivity and the type of revenue recognized. It was determined that these differences did not allow for an accurate apples to apples comparison of patient service revenue pre-pandemic versus during the pandemic.

We concur with the finding that Option (iii) should have been selected as the methodology used in determining lost revenue for Provider Relief Fund reporting. We plan to make the necessary corrections to the change in methodology for period 1 & 2 reporting while submitting our period 4 reporting by March 31, 2023.

HRSA was contacted before September 30, 2022 and we were instructed that any changes in methodology would need to be made during our next open reporting period. This window has just opened on January 1, 2023 and corrections will be made for this reporting methodology by March 31, 2023. We plan to make the necessary corrections to the change in methodology for period 1 & 2 reporting while submitting our period 4 reporting by March 31, 2023.

Contact Name: Michael J. Neuman
Senior Vice President – Finance
neuman@kennedykrieger.org
443-923-1810

Sincerely,

A handwritten signature in cursive script that reads "Michael J. Neuman".

Michael J. Neuman
Senior Vice President - Finance